课题基金 / 基金详情

CHRONIC AMPHETAMINE ADMINISTRATION IN SCHIZOPHRENIC

CHRONIC AMPHETAMINE ADMINISTRATION IN SCHIZOPHRENIC
精神分裂症患者长期服用安非他明
批准号:
3860021
负责人:
L B BIGELOW
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

L B BIGELOW的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Persistent deficit symptoms represent the most disabling of the schizophrenic symptoms that are likely to remain after the productive or positive symptoms are treated with available neuroleptics. Those patients who appear to benefit from the acute administration of amphetamine are asked to participate in a 6 week trial of daily oral dosing with amphetamine. To date, two patients have completed this double blind placebo controlled trial. One appeared to benefit modestly, the other showed no obvious change. Formal statistical analysis will await the acculmination of adequate numbers of patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TREATMENT OF MIGRAINE WITH ANIONIC POLYELECTROLYTES
PENTOSAN POLYSULFATE AS PROPHYLAXIS FOR MIGRAINE
CHRONIC AMPHETAMINE ADMINISTRATION IN SCHIZOPHRENIA
ANTI-HIV POTENTIAL OF PENTOSAN POLYSULFATE
海外基金